HARROW HEALTH, INC. (26) | Business Finance (12)

Browse by Subcategory

Recent Contracts

Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B. Riley Securities, Inc (Filed With SEC on May 5, 2021)
Underwriting Agreement, dated as of April 15, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 20, 2021)
Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (Filed With SEC on August 10, 2020)
First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Underwriting Agreement, dated as of April 8, 2021, by and among Harrow Health, Inc., Eton Pharmaceuticals, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)
Asset Purchase Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Loan Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Joinder and Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC (Filed With SEC on May 29, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated December 11, 2018 between Imprimis Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc (Filed With SEC on February 5, 2019)